DOCSLIB.ORG

Neuroscience Products

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Neuroscience Products Neuroscience Products CATALOG CATALOG NUMBER U.S. $ NUMBER U.S. $ -A- 3-(N-ACETYLAMINO)-5-(N-DECYL-N- 1 mg 27.50 159549 METHYLAMINO)BENZYL ALCOHOL 5 mg 89.40 o A23187 0-5 C [103955-90-4] (ADMB) See: Antibiotic A23187 A Protein Kinase C activator. Ref.: Proc. Nat. Acad. Sci. USA, 83, 4214 AA-861 20 mg 72.70 (1986). 159061 Purity: 95% 100 mg 326.40 C20H34N2O2 MW 334.5 0oC Orally active, specific and potent inhibitor of 5-lipoxygenase. N-ACETYL-ASP-GLU 25 mg 45.00 153036 [3106-85-2] 100 mg 156.00 Ref.: 1. Yoshimoto, T., et.al., Biochim. o Biophys. Acta, 713, 470 (1982). 2. Ashida, -20-0 C An endogenous neuropeptide with high 250 mg 303.65 Y., et.al., Prostaglandins, 26, 955 (1983). 3. affinity for a brain "Glutamate" receptor. Ancill, R.J., et.al., J. Int. Med. Res., 18, 75 Ref: Zaczek, R., et al., Proc. Natl. Acad. (1990). Sci. (USA), 80, 1116 (1983). C21H26O3 MW 326.4 C11H16N2O8 MW 304.3 ABL PROTEIN TYROSINE KINASE 250 U 47.25 N-ACETYL-2-BENZYLTRYPTAMINE 195876 (v-abl) 1 KU 162.75 See: Luzindole -70oC Recombinant Expressed in E. coli ACETYL-DL-CARNITINE 250 mg 60.00 A truncated form of the v-abl protein 154690 [2504-11-2] 1 g 214.00 tyrosine kinase which contains the 0oC Hydrochloride minimum region needed for kinase activity Crystalline and fibroblast transformation. Suppresses C9H17NO4 • HCl MW 239.7 apoptosis and induces resistance to anti-cancer compounds. O-ACETYL-L-CARNITINE CHLORIDE 500 mg 11.45 Activity: 100 KU/ml 159062 [5080-50-2] 1 g 20.65 Unit Definition: one unit is the amount of 0-5oC (R-(-)-2-Acetyloxy-3-carboxy-N,N,N-trimethyl 5 g 97.45 enzyme which catalyzes the transfer of 1 -1-propanaminium chloride) pmol of phosphate to EAIYAAPFAKKK per Purity: >88% minute at 30°C, pH 7.5. A cholinergic agonist that stimulates Contains no detectable phosphatase and neuronal response to serotonin and protease and only trace amounts of RNase acetylcholine. and DNase. C9H18NO4Cl MW 239.7 MW 45 kDa ACETYLCHOLINE CHLORIDE, 50µCi 251.35 17032 14 250µCi 995.00 ACACETIN 10 mg 17.50 o [ACETYL-1- C] 193972 [480-44-4] 50 mg 85.00 0-5 C Sp. Act. 1-10 mCi/mmol 0-5oC (5,7-Dihydroxy-4′-methoxyflavone) 37-370 MBq/mmol Possesses antioxidant properties and an Ethanol inhibitor of rat liver glutathione Ref.: Nicholas, C., et al., J. Neurochem., S-transferase. 62, 1835-1839 (1994). Ref.: Zhang, K. and Das, N.P., Biochem. CH3CO2CH2CH2N(CH3)3Cl MW 181.6 Pharmacol., 47, 2063 (1994). ACETYL COENZYME A 1 mg 11.25 C16H12O5 MW 284.3 100490 [72-89-9] 5 mg 27.85 o ACETATE KINASE 250 U 50.00 0 C Trilithium Salt 10 mg 50.50 154678 [9027-42-3] 1 KU 189.80 Trihydrate 25 mg 111.15 o Purity: 92-95% 100 mg 359.00 0-5 C (ATP: Acetate phosphotransferase) • EC 2.7.2.1 C23H35Li3N7O17P3S 3H2O MW 881.1 From Escherichia coli N-ACETYL-L-CYSTEINE 25 g 22.00 Activity: 150-300 units/mg protein (Biuret). 100098 [616-91-1] 50 g 36.75 Unit Definition: One unit will 0-5oC Crystalline 100 g 66.25 phosphorylate 1.0 µmole of acetate to Purity: >96% 500 g 223.30 acetylphosphate per min at pH 7.6 at 25°C. A mucolytic agent for isolation of 1 kg 365.20 Suspension in 3.2 M (NH4)2SO4 solution, mycobacteria from sputum. pH approx. 6.0. C5H9NO3S MW 163.2 Contains less than 0.01% glutamic-oxalacetic transaminase, lactic N-ACETYL-L-CYSTEINE 5 g 12.75 dehydrogenase, myokinase and NADH 194603 [616-91-1] 10 g 20.00 oxidase. 0-5oC Cell Culture Reagent 25 g 28.10 Crystalline 50 g 45.00 ACETOHEXAMIDE 1 g 22.05 Purity: >96% 100 g 84.25 193572 [968-81-0] 5 g 88.20 A mucolytic agent for isolation of 500 g 260.20 RT (4-Acetyl-N-[(cyclohexylamino)- mycobacteria from sputum. carbonyl]benzenesulfonamide) C5H9NO3S MW 163.2 Hypoglycemic agent 14 L µ 1332.80 C15H20N2O4S MW 324.4 N-ACETYL- -CYSTEINE, [1- C] 50 Ci 16010 Sp. Act. 25-50 mCi/mmol o ACETOPROMAZINE 1 g 10.30 0-5 C 0.925-1.85 GBq/mmol 154683 [61-00-7] Ethanol solution. RT (2-Acetyl-10-[3-dimethyl-aminopropyl]phenot HSCH2CH(NHCOCH3)COOH hiazine) MW 163.2 Maleate Salt • 4-ACETYL-1,1-DIMETHYL- 5 mg 59.65 C19H22N2OS C4H4O4 MW 442.5 159683 PIPERAZINIUM IODIDE 10 mg 108.95 N-[2-(ACETOXY)ETHYL]-3- 1 mg 19.00 RT A nicotinic acid agonist 25 mg 217.85 159681 PYRIDINECARBOXAMIDE 5 mg 75.00 C8H17N2OI MW 284.1 o 0-5 C (Nicorandil Analog; SG-209) 10 mg 121.00 N-ACETYLDOPAMINE 10 mg 16.80 An analog of nicorandil that acts as a 25 mg 253.00 150229 [2494-12-4] 25 mg 33.10 nitrate-free vasodilator through activation of 0oC Crystalline 100 mg 90.10 potassium channels. Metabolite of dopamine 500 mg 247.20 C10H12N2O3 MW 207.2 C10H13NO3 MW 195.2 To place an order: (800) 854-0530, fax (800) 334-6999 1146 www.icnbiomed.com Outside the U.S.: (714) 545-0100, fax (714) 557-4872 Email: [email protected] Neuroscience Products CATALOG CATALOG NUMBER U.S. $ NUMBER U.S. $ γ-ACETYLENIC GABA 1 mg 11.00 N-α-ACETYLGLYCYL-L-LYSINE 100 mg 8.80 193573 [57659-38-3] 5 mg 44.10 100182 METHYL ESTER 250 mg 17.80 RT (4-Amino-5-hexynoic acid) 25 mg 198.45 0oC [14752-92-2] 1 g 60.90 A GABA transaminase inhibitor. (AGLME) 5 g 280.55 Ref.: Schousboe, et al., Neurochem. Res., Acetate Salt 11, 1497 (1986). Crystalline C6H9NO2 MW 127.1 Substrate for measurement of urokinase activity. Ref.: Walton, P.L., Biochem. Biophys. Acta, N-ACETYL-S-FARNESYL-L-CYSTEINE 5 mg 71.35 132, 104 (1967). 159030 (AFC) 25 mg 306.00 C11H21N3O4 • C2H4O2 MW 319.4 o -20 C Purity: 98% 5 mg 59.65 Specific inhibitor of S-farnesyl- 1-ACETYL-4-METHYLPIPERAZINE cysteinemethyl transferase. Also prevents 159684 Hydrochloride 10 mg 108.95 carboxyl methylation of p21ras RT A nicotinic acid agonist 25 mg 217.85 platelet RAP C H N O • HCl MW 178.7 1 and the transduction γ subunit. 7 14 2 Ref.: 1. Volker, C., et.al., J. Biol. Chem., N-ACETYLNEURAMINIC ACID 10 mg 12.65 266, 21515 (1991). 2. Huzoor-Akabar, 194605 [131-48-6] 25 mg 25.35 et.al., ibid., 266, 4387 (1991). 3. 0-5oC (Sialic Acid; NANA; Type IV) 100 mg 66.15 Perez-Sala, D., et.al., Proc. Natl. Acad. Sci. Cell Culture Reagent 250 mg 145.55 USA, 88, 3043 (1991). From E. coli 500 mg 248.05 MW 367.5 White crystalline powder 1 g 439.90 Purity: ≥98% C11H19NO9 MW 309.3 N-ACETYL-S-FARNESYL-L- 50 µCi 605.15 3 5 mg 10.50 26020 CYSTEINE, [Cysteine-1- H] 250 µCi 1817.90 N-ACETYLNEURAMINIC ACID o 195854 [131-48-6] 25 mg 37.80 0-5 C Sp. Act. 10-20 Ci/mmol o 370-740 MBq/mmol 0-5 C (Sialic Acid; NANA) 100 mg 131.25 Ethanol From Bovine Milk Shipped in dry ice. C11H19NO9 MW 309.3 Please call for delivery information. N-ACETYLNEURAMINIC ACID 10 mg 12.60 MW 367.5 195855 [131-48-6] 50 mg 52.50 0-5oC (Sialic Acid; NANA) 250 mg 236.25 From Egg N-ACETYL-S-GERANYL-L-CYSTEINE 1 mg 20.20 Purity: ≥97% 195681 (AGC) 5 mg 92.40 C11H19NO9 MW 309.3 -20oC Purity: 98% A biologically inactive close structural N-ACETYL-PHE-NLE-ARG-PHE 0.5 mg 18.00 153039 1 mg 30.00 analog of AFC and AGGC. Used as a o AMIDE negative control. -20-0 C [83903-28-0] 5 mg 131.00 MW 299.4 A molluscan cardioexcitatory neuropeptide analog. C23H46N8O5 MW 622.8 N-ACETYL-S-GERANYLGERANYL-L- 5 mg 131.90 N-ACETYLPROCAINAMIDE 250 mg 11.95 159845 10 mg 229.30 193574 1 g 37.95 o CYSTEINE [34118-92-8] -20 C [139332-94-8] -20oC (4-(Acetylamino)-N-[2-(diethylamino)ethyl]ben (AGGC) zamide) Purity: 98% Hydrochloride Specifically inhibits methyl esterification of A metabolite of procainamide that blocks geranylgeranylated proteins. Also, it blocks potassium channels and exhibits some signal transduction in human neutrophils antiarrhythmic activity. that are receptor mediated. C15H23N3O2 • HCl MW 313.8 Ref.: 1. Phillips, M.R., et al., Science, 259, 977 (1993). N-ACETYL-D-SPHINGOSINE 1 mg 12.10 158923 [3102-57-6] 5 mg 40.20 2. Volker, C., et al., FEBS Lett., 295, 189 o (1991). -20 C (C2 Ceramide; N-Ethanoyl-D-sphingosine; MW 435.7 Acetyl ceramide) Purity: 98% Inhibitor of cell proliferation and inducer of β 1 mg 28.00 monocytic differentiation of HL-60 cells. N-ACETYL-D-GLUCOSAMINYL- - Stimulates cytosolic serine/threonine 158221 → 5 mg 125.95 o (1 4)-N-ACETYLMURAMYL-L- protein phosphatase in T9 cells at low -20 C ALANYL-D-ISOGLUTAMINE concentrations. (GMDP) Ref.: 1. Kim, M.-Y., et.al., J. Biol. Chem., Purity: 98% 266, 484 (1991). 2. Okazaki, T., et.al., ibid., Lyophilized 265, 15823 (1990). 3. Dobrowsky, R.T. and A novel synthetic analog of bacterial cell Hannun, Y.A., et.al., J. Biol. Chem., 267, wall glycopeptide which acts as a 5048 (1992).
Load more

Recommended publications
  • Characterisation of the Α1b-Adrenoceptor by Modeling, Dynamics and Virtual Screening Kapil Jain B.Pharm, M.S.(Pharm.)
    Characterisation of the α1B-Adrenoceptor by Modeling, Dynamics and Virtual Screening Kapil Jain B.Pharm, M.S.(Pharm.) A Thesis submitted for the degree of Master of Philosophy at The University of Queensland in 2018 Institute for Molecular Bioscience 0 Abstract G protein-coupled receptors (GPCRs) are the largest druggable class of proteins yet relatively little is known about the mechanism by which agonist binding induces the conformational changes necessary for G protein activation and intracellular signaling. Recently, the Kobilka group has shown that agonists, neutral antagonists and inverse agonists stabilise distinct extracellular surface (ECS) conformations of the β2-adrenergic receptor (AR) opening up new possibilities for allosteric drug targeting at GPCRs. The goal of this project is to extend these studies to define how the ECS conformation of the α1B-AR changes during agonist binding and develop an understanding of ligand entry and exit mechanisms that may help in the design of specific ligands with higher selectivity, efficacy and longer duration of action. Two parallel approaches were initiated to identify likely functional residues. The role of residues lining the primary binding site were predicted by online web server (Q-Site Finder) while secondary binding sites residues were predicted from molecular dynamics (MD) simulations. Predicted functionally significant residues were mutated and their function was established using FLIPR, radioligand and saturation binding assays. Despite the α1B-AR being pursued as a drug target for over last few decades, few specific agonists and antagonists are known to date. In an attempt to address this gap, we pursued ligand-based approach to find potential new leads.
    [Show full text]
  • Effects of Mimosine Administered to a Perfused Area of Skin in Angora Goats by R
    Downloaded from British Journal of Nutrition (1996), 15, 69-19 69 https://www.cambridge.org/core Effects of mimosine administered to a perfused area of skin in Angora goats BY R. PUCHALA, S. G. PIERZYNOWSKI, T. SAHLU* AND S. P. HART E. (Kika) de la Garza Institute for Goat Research, Langston University, Langston, Oklahoma 73050, USA . IP address: (Received I1 November 1994 - Revised 15 March 1995 -Accepted I1 May 1995) 170.106.34.90 The effect of mimosine on a perfused area of skin tissue was studied using an isolated perfusion technique. Four mature Angora wethers (body weight 35 (SE 2.3) kg) were cannulated bilaterally with indwelling silicone catheters in the superficial branches of the deep circumflex iliac artery and vein. Mimosine , on (40 mg/kg metabolic weight (Wo75)per d) was infused intra-arterially into one iliac artery of each goat for 3 d and saline was infused in the contralateral (control) iliac artery. Iliac venous blood samples were 27 Sep 2021 at 22:01:16 taken from both sides along with arterial samples from the carotid artery. Mimosine infusion elevated plasma mimosine in the carotid artery (52.6 (SEM19.21) pol/l) and iliac vein on the saline-treated side to 54.1 (SEM 16-31)~ol/l and in the iliac vein on the mimosine-treated side to 191.3 (SEM1914) pmol/l (P < 0.01). Mimosine decreased feed intake (2.3 v. 0.6 kg/d, ~~~0.29;P < 0.001) and water consumption (5-2 v. 1.3 litres/d, SEM 0.67; P < 0.001).
    [Show full text]
  • Review on the Nutritive Value and Toxic Aspects of Leucaena Leucocephala
    Trop Anim Prod 1979 4:2 113 A REVIEW ON THE NUTRITIVE VALUE AND TOXIC ASPECTS OF LEUCAENA LEUCOCEPHALA U ter Meulen1, S Struck1, E Schulke2 and E A El Harith1 1 Institut fur Tierphysiologie und Tierernahrung der Universitat Gottingen Oskar-Kellner-Weg 6, Weende 3400 Gottingen, West Germany This review discusses the nutritive value of Leucaena leucocephala and its mimosine toxicity when used as a forage for livestock. Chemical analysis and feeding trial. have indicated that Leucaena leaf-meal with its high protein, calcium, -carotene and xanthophyll contents, is potentially a valuable feed for livestock in the tropics. The symptoms of mimosine toxicity in cattle, sheep, poultry, goats horses, pigs and rats ire discussed, The chemical value of mimosine and the possible mechanism of its toxicity are reviewed. Possible solutions to the toxicity problem are presented together with the suggestion that further studies be initiated to overcome this problem. Key Words: Leucaena, mimosine toxicity, livestock, forage, feeding trials The uses of the tropical legume Leucaena leucocephala are quite versatile. These uses include its function as a source of firewood and timber,its role in soil erosion control (Dijkman 1950), its ability to provide shade for other plants as well as its function in maintaining the fertility of the soil and of serving as a nutritious forage for animal feed (Ruskln 1977). Presently the greatest use of this plant in animal nutrition is its incorporation in cattle feed. Leucaena leaf-meal, with its rich protein, minerals and vitamin content, is also becoming a popular ingredient in poultry feeds in the tropics (D'Mello and Taplin 1978).
    [Show full text]
  • (12) United States Patent (10) Patent No.: US 9,498,481 B2 Rao Et Al
    USOO9498481 B2 (12) United States Patent (10) Patent No.: US 9,498,481 B2 Rao et al. (45) Date of Patent: *Nov. 22, 2016 (54) CYCLOPROPYL MODULATORS OF P2Y12 WO WO95/26325 10, 1995 RECEPTOR WO WO99/O5142 2, 1999 WO WOOO/34283 6, 2000 WO WO O1/92262 12/2001 (71) Applicant: Apharaceuticals. Inc., La WO WO O1/922.63 12/2001 olla, CA (US) WO WO 2011/O17108 2, 2011 (72) Inventors: Tadimeti Rao, San Diego, CA (US); Chengzhi Zhang, San Diego, CA (US) OTHER PUBLICATIONS Drugs of the Future 32(10), 845-853 (2007).* (73) Assignee: Auspex Pharmaceuticals, Inc., LaJolla, Tantry et al. in Expert Opin. Invest. Drugs (2007) 16(2):225-229.* CA (US) Wallentin et al. in the New England Journal of Medicine, 361 (11), 1045-1057 (2009).* (*) Notice: Subject to any disclaimer, the term of this Husted et al. in The European Heart Journal 27, 1038-1047 (2006).* patent is extended or adjusted under 35 Auspex in www.businesswire.com/news/home/20081023005201/ U.S.C. 154(b) by Od en/Auspex-Pharmaceuticals-Announces-Positive-Results-Clinical M YW- (b) by ayS. Study (published: Oct. 23, 2008).* This patent is Subject to a terminal dis- Concert In www.concertpharma. com/news/ claimer ConcertPresentsPreclinicalResultsNAMS.htm (published: Sep. 25. 2008).* Concert2 in Expert Rev. Anti Infect. Ther. 6(6), 782 (2008).* (21) Appl. No.: 14/977,056 Springthorpe et al. in Bioorganic & Medicinal Chemistry Letters 17. 6013-6018 (2007).* (22) Filed: Dec. 21, 2015 Leis et al. in Current Organic Chemistry 2, 131-144 (1998).* Angiolillo et al., Pharmacology of emerging novel platelet inhibi (65) Prior Publication Data tors, American Heart Journal, 2008, 156(2) Supp.
    [Show full text]
  • Download Product Insert (PDF)
    Product Information CNQX Item No. 14618 CAS Registry No.: 115066-14-3 Formal Name: 1,2,3,4-tetrahydro-7-nitro-2,3-dioxo-6- quinoxalinecarbonitrile H Synonyms: 6-cyano-7-Nitroquinoxaline-2,3-dione, NC N O FG 9065 MF: C9H4N4O4 FW: 232.2 O O N N Purity: ≥98% 2 Stability: ≥2 years at -20°C H Supplied as: A crystalline solid λ UV/Vis.: max: 217, 275, 315 nm Laboratory Procedures For long term storage, we suggest that CNQX be stored as supplied at -20°C. It should be stable for at least two years. CNQX is supplied as a crystalline solid. A stock solution may be made by dissolving the CNQX in the solvent of choice. CNQX is soluble in organic solvents such as DMSO and dimethyl formamide (DMF), which should be purged with an inert gas. The solubility of CNQX in these solvents is approximately 5 and 12 mg/ml, respectively. CNQX is sparingly soluble in aqueous buffers. For maximum solubility in aqueous buffers, CNQX should first be dissolved in DMF and then diluted with the aqueous buffer of choice. CNQX has a solubility of approximately 0.5 mg/ml in a 1:1 solution of DMF:PBS (pH 7.2) using this method. We do not recommend storing the aqueous solution for more than one day. CNQX is a competitive, non-NMDA glutamate receptor antagonist (IC50s = 0.3 and 1.5 μM for AMPA and kainate 1,2 receptors, respectively, versus IC50 = 25 μM for NMDA receptors). This compound has been used to specifically target AMPA and kainate receptor responses and thus differentiate from that of NMDA receptors.
    [Show full text]
  • An Investigation Into Pro-Apoptotic Targets in Experimental Glaucoma and the Neuroprotective Effects of Ginkgo Biloba in Retinal Ganglion Cells
    An investigation into pro-apoptotic targets in experimental glaucoma and the neuroprotective effects of Ginkgo biloba in retinal ganglion cells Abeir Baltmr MB ChB, FRCS (Glasg) A thesis submitted to University College London for the degree of Doctor of Medicine (Research) 2012 Glaucoma and Retinal Neurodegeneration Research Group Visual Neuroscience Institute of Ophthalmology 1 Declaration I, Abeir Baltmr, confirm that the work presented in this thesis is my own. Where information has been derived from other sources, I confirm that this has been indicated in the thesis. Abeir Baltmr 2 Abstract Ginkgo biloba has been advocated as a neuroprotective agent for several years in glaucoma. In this study, immunohistochemistry was used to identify known potential molecular targets of Ginkgo biloba related to retinal ganglion cell (RGC) apoptosis in experimental glaucoma, including amyloid precursor protein (APP), Aß, cytochrome c, caspase-3 and tumor necrosis factor receptor-1 (TNF-R1). Furthermore, using apoptotic inducers related to mechanisms implicated in glaucoma, namely Dimethyl sulphoxide (DMSO), ultraviolet C (UVC) and Sodium Azide (NaN3), the effects of the terpenoid fraction of Ginkgo biloba (Ginkgolide A, Ginkgolide B and Bilobalide) were investigated separately in cultured retinal ganglion cells (RGC-5). Cell viability was determined by 3-(4,5-dimethylthiazol-2-yl)-2,5- diphenyltetrazolium bromide (MTT) assay and morphological analysis of DMSO treated RGC-5 was performed using Hoechst 33342 stain. Immunohistochemistry showed a strong inverse correlation between Aß and APP in ocular hypertension (OHT) animals, with APP and Aß accumulation peaking at 1 and 12 weeks after intraocular pressure (IOP) elevation respectively. Cytochrome c and TNF-R1 expression peaked at 3 weeks, and active caspase 3 activity at 12 weeks after IOP elevation.
    [Show full text]
  • Effect of Theophylline and Enprofylline on Bronchial Hyperresponsiveness
    Thorax: first published as 10.1136/thx.44.12.1022 on 1 December 1989. Downloaded from Thorax 1989;44:1022-1026 Effect of theophylline and enprofylline on bronchial hyperresponsiveness G H KOETER, J KRAAN, M BOORSMA, J H G JONKMAN, TH W VAN DER MARK From the Department ofPulmonology and Lung Function, University Hospital, Groningen; Pharma Bio Research, Assen; and Astra Pharmaceutica, Rijswijk, The Netherlands ABSTRACT The effect of increasing intravenous doses of theophylline and enprofylline, a new xanthine derivative, on bronchial responsiveness to methacholine was studied in eight asthmatic patients. Methacholine provocations were carried out on three days before and after increasing doses of theophylline, enprofylline, and placebo, a double blind study design being used. Methacholine responsiveness was determined as the provocative concentration of methacholine causing a fall of 20% in FEV, (PC20). The patients were characterised pharmacokinetically before the main study to provide an individual dosage scheme for each patient that would provide rapid steady state plasma concentration plateaus of 5, 10, and 15 mg/l for theophylline and 1 25, 2 5, and 3-75 mg/l for enprofylline. Dose increments in the main study were given at 90 minute intervals. FEV, showed a small progressive decrease after placebo; it remained high in relation to placebo after both drugs and this effect was dose related. Methacholine PC20 values decreased after placebo; mean values were (maximum difference 2-0 and 1 7 higher after theophylline and enprofylline than after placebo copyright. doubling doses of methacholine); the effect of both drugs was dose related. Thus enprofylline and theophylline when given intravenously cause a small dose related increase in FEV1 and methacholine PC20 when compared with placebo.
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2015/0025060A1 Tamarkin Et Al
    US 2015.0025060A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2015/0025060A1 Tamarkin et al. (43) Pub. Date: Jan. 22, 2015 (54) FOAMABLE COMPOSITIONS AND KITS (30) Foreign Application Priority Data COMPRISING ONE ORMORE OF A CHANNEL AGENT, ACHOLINERGICAGENT, Oct. 25, 2002 (IL) .......................................... 1524.86 A NITRC OXDE DONOR AND RELATED AGENTS AND THEIR USES Publication Classification (71) Applicant: Foamix Pharmaceuticals Ltd., Rehovot (51) Int. Cl. (IL) A613 L/554 (2006.01) A 6LX3 L/505 (2006.01) (72) Inventors: Dov Tamarkin, Macabim (IL); Meir A647/10 (2006.01) Eini, Ness Ziona (IL); Doron Friedman, A613 L/4422 (2006.01) Karmei Yosef (IL); Tal Berman, Rishon (52) U.S. Cl. Le Ziyyon (IL); Alex Besonov, Rehovot CPC ........... A6 IK3I/554 (2013.01); A61 K3I/4422 (IL) (2013.01); A61 K3I/505 (2013.01); A61 K 47/10 (2013.01) (21) Appl. No.: 14/448,670 USPC ....................... 514/211.03: 514/356; 514/275 (22) Filed: Jul. 31, 2014 (57) ABSTRACT Related U.S. Application Data The present invention relates to a foamable therapeutic com position comprising: (a) a therapeutically effective concen (63) Continuation of application No. 1 1/767,442, filed on tration of at least one active agent selected from the group Jun. 22, 2007, which is a continuation-in-part of appli consisting of a channel agent, a cholinergic agent, and a nitric cation No. 10/911.367, filed on Aug. 4, 2004, said oxide donor; and (b) a foamable carrier comprising: application No. 1 1/767,442 is a continuation-in-part of i.
    [Show full text]
  • In Vitro Pharmacology of Clinically Used Central Nervous System-Active Drugs As Inverse H1 Receptor Agonists
    0022-3565/07/3221-172–179$20.00 THE JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS Vol. 322, No. 1 Copyright © 2007 by The American Society for Pharmacology and Experimental Therapeutics 118869/3215703 JPET 322:172–179, 2007 Printed in U.S.A. In Vitro Pharmacology of Clinically Used Central Nervous System-Active Drugs as Inverse H1 Receptor Agonists R. A. Bakker,1 M. W. Nicholas,2 T. T. Smith, E. S. Burstein, U. Hacksell, H. Timmerman, R. Leurs, M. R. Brann, and D. M. Weiner Department of Medicinal Chemistry, Leiden/Amsterdam Center for Drug Research, Vrije Universiteit Amsterdam, Amsterdam, The Netherlands (R.A.B., H.T., R.L.); ACADIA Pharmaceuticals Inc., San Diego, California (R.A.B., M.W.N., T.T.S., E.S.B., U.H., M.R.B., D.M.W.); and Departments of Pharmacology (M.R.B.), Neurosciences (D.M.W.), and Psychiatry (D.M.W.), University of California, San Diego, California Received January 2, 2007; accepted March 30, 2007 Downloaded from ABSTRACT The human histamine H1 receptor (H1R) is a prototypical G on this screen, we have reported on the identification of 8R- protein-coupled receptor and an important, well characterized lisuride as a potent stereospecific partial H1R agonist (Mol target for the development of antagonists to treat allergic con- Pharmacol 65:538–549, 2004). In contrast, herein we report on jpet.aspetjournals.org ditions. Many neuropsychiatric drugs are also known to po- a large number of varied clinical and chemical classes of drugs tently antagonize this receptor, underlying aspects of their side that are active in the central nervous system that display potent effect profiles.
    [Show full text]
  • Antagonism of Histamine-Activated Adenylate Cyclase in Brain by D
    Proc. Natl. Acad. Sci. USA Vol.74, No. 12, pp. 5697-5701, December 1977 Medical Sciences Antagonism of histamine-activated adenylate cyclase in brain by D-lysergic acid diethylamide (histaminergic antagonists/adenosine 3':5'-cyclic monophosphate/H2-receptors/ergots/D-2-bromolysergic acid diethylamide) JACK PETER GREEN, CARL LYNN JOHNSON, HAREL WEINSTEIN, AND SAUL MAAYANI Department of Pharmacology, Mount Sinai School of Medicine of the City University of New York, 100th Street and Fifth Avenue, New York, New- York 10029 Communicated by Vincent P. Dole, August 19, 1977 ABSTRACT D-Lysergic acid diethylamide and D-2-bro- (ED50; amount necessary to produce half-maximal response) molysergic acid diethylamide are competitive antagonists of and antagonist affinities (pA2) were not altered. the histamine activation of adenylate cyclase [ATP pyrophos- Adenylate Cyclase Assay. The assay system has been de- phate-lyase (cyclizing); E.C. 4.6.1.11 in broken cell preparations in All additions of the hippocampus and cortex of guinea pig brain. The ade- scribed (8). All assays were performed triplicate. nylate cyclase is linked to the histamine H2-receptor. Both D- were made to the assay tubes on ice. They were then transferred lysergic acid diethylamide and D-2-bromolysergic acid dieth- to a 30° shaking incubator and preincubated for 5 min to allow ylamide show topological congruency with potent H2-antago- the enzymatic activity to reach a steady state and to eliminate nists. D-2-Bromolysergic acid diethylamide is 10 times more the influence of any lag periods in hormone activation. After potent as an H2-antagonist than cimetidine, which has been the the preincubation period, 25 of [a-32PJATP (1-2 gCi) were most potent H2-antagonist reported, and D-lysergic acid di- pl ethylamide is about equipotent to cimetidine.
    [Show full text]
  • Programa / Program
    ABSTRACTS / RESÚMENES LUNES 13 DE DICIEMBRE / MONDAY, DECEMBER 13 INAUGURAL PLENARY LECTURES / CONFERENCIAS PLENARIAS INAUGURALES PL-01 THE CONCURRENT CHALLENGES OF EFFECTIVENESS RESEARCH AND INDIVIDUALIZED THERAPEUTIC STRATEGIES Gianni Tognoni South Institute for Pharmacological Research, Santa María Imbaro, Chiety, Italy. email: [email protected] The proposal of focusing the attention on the two apparent extremes of care (on one side the public health relevance and transferability of the paradygm of EBM, on the other side one of the expected clinical yields of genomic-translational research) aims to underline and exemplify the strict complementarity of the two scenarios. Methodologically and operationally, both approaches do propose a very promising future for the development of pharmacological research, with closer links to the highly productive area of outcomes- oriented epidemiology and with the most advanced sector of basic sciences. It seems specifically important that the two areas could be developed in close interaction, possibly within the same department(s), to assure a productive interplay of competences in the collaboration with clinical care, as well as in the training of the new generations of pharmacologists, pharmacists, clinicians. PL-02 BASIC PERIPHERAL MOLECULAR COMPONENTS OF INFLAMMATORY PAIN H Ferreira School of Medicine of Ribeirão Preto. Department of Pharmacology, Campus USP, Ribeirão Preto, SP. Brazil. email: [email protected] When non steroidal anti-inflammatory drugs mechanism of action was discovered, I proposed that their analgesic effect resulted from the prevention of the nociceptor sensitization by prostaglandins. Thus, pain in an inflammatory process results from an action of mechanical, thermal or chemical stimuli upon sensitized nociceptors (hiperalgesia, hypernociception-HPr).
    [Show full text]
  • Vimpat, INN-Lacosamide
    European Medicines Agency Evaluation of Medicines for Human Use Doc.Ref.: EMEA/460925/2008 ASSESSMENT REPORT FOR Vimpat International Nonproprietary Name: lacosamide Procedure No. EMEA/H/C/000863 Assessment Report as adopted by the CHMP with all information of a commercially confidential nature deleted. 7 Westferry Circus, Canary Wharf, London, E14 4HB, UK Tel. (44-20) 74 18 84 00 Fax (44-20) 75 23 70 51 E-mail: [email protected] http://www.emea.europa.eu © European Medicines Agency, 2008. Reproduction is authorised provided the source is acknowledged TABLE OF CONTENTS Page 1. BACKGROUND INFORMATION ON THE PROCEDURE........................................... 3 1.1 Submission of the dossier ........................................................................................................ 3 1.2 Steps taken for the assessment of the product.......................................................................... 3 2 SCIENTIFIC DISCUSSION................................................................................................. 4 2.1 Introduction.............................................................................................................................. 4 2.2 Quality aspects......................................................................................................................... 4 2.3 Non-clinical aspects............................................................................................................... 11 2.4 Clinical aspects .....................................................................................................................
    [Show full text]